Company Info

PepGen

Overview

PepGen is harnessing the power of our Enhanced Delivery Oligonucleotide technology to solve the challenge of getting oligonucleotides to where they need to be to work, and to realize the clinical potential of oligonucleotide therapies to transform the lives of people living with neuromuscular diseases.

We are advancing a new generation of genetic therapies to transform the treatment of neuromuscular and neurologic diseases. Oligonucleotide therapies have long promised to transform healthcare with their ability to specifically target RNA sequences that cause disease, and yet the efficacious delivery of these targeted therapies has lagged and remains a major challenge. Our proprietary Enhanced Delivery Oligonucleotide (EDO) platform has shown the potential to treat such genetic disorders by optimizing the safe and efficient delivery of therapeutic oligonucleotide cargos into affected tissues and cells, thereby addressing the key challenge that has impeded the clinical translation and validation of this class of molecules. We have leveraged these characteristics to develop a robust pipeline of world-leading therapeutics for the treatment of serious genetic diseases.

Backed by world-leading investors, privately-held PepGen is headquartered in Boston, Massachusetts.

Contributors

Michelle Mellion, M.D.

James McArthur, Ph.D.

Company Info

PepGen

Overview

Contributors

Contributions

In which orphan spaces or unmet medical needs do you think we will see the next treatment innovations?

Q: What’s the key to being a leader in the industry?